Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: Efficacy summary

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  O'riordan, William ^a   Green, Sinikka ^a   Mehra, Purvi ^a   De Anda, Carisa ^b   Fang, Edward ^b   Prokocimer, Philippe ^b  

^a ECMC Department of Surgery   (United States)

^b Cubist Pharmaceuticals   (United States)

Author keywords

ABSSSI; efficacy; MRSA; Staphylococcus aureus; tedizolid phosphate

Indexed keywords

LINEZOLID; PLACEBO; TEDIZOLID;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ARTICLE; BACTERIAL SKIN DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTENTION TO TREAT ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ABSSSI; EFFICACY; MRSA; STAPHYLOCOCCUS AUREUS; TEDIZOLID PHOSPHATE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; ORGANOPHOSPHATES; OXAZOLES; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

EID: 84892164408     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit617     Document Type: Article

References (45)

1. Lipsky BA, Moran GJ, Napolitano LM, Vo L, Nicholson S, Kim M. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: Clinical characteristics, medical treatment, and outcomes. BMC Infect Dis 2012; 12:227
2. Talan DA, Krishnadasan A, Gorwitz RJ, et al.; EMERGEncy ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53:144-9
3. May AK, Stafford RE, Bulger EM, et al.; Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10:467-99
4. Jarvis WR, Jarvis AA, Chinn RY. National prevalence of methicillinresistant Staphylococcus aureus in inpatients at United States health care facilities, 2010. Am J Infect Control 2012; 40:194-200
5. de Kraker ME, Wolkewitz M, Davey PG, Grundmann H; BURDEN Study Group. Clinical impact of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55:1598-605
6. Stefani S, Chung DR, Lindsay JA, et al. Methicillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012; 39:273-82
7. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008; 51:291-8
8. Qualls ML, Mooney MM, Camargo CA Jr, Zucconi T, Hooper DC, Pallin DJ. Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated methicillin-resistant Staphylococcus aureus, 1997-2007. Clin Infect Dis 2012; 55:103-5
9. Bush K. Improving known classes of antibiotics: An optimistic approach for the future. Curr Opin Pharmacol 2012; 12:527-34
10. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009; 66:82-98
11. Shlaes DM, Spellberg B. Overcoming the challenges to developing new antibiotics. Curr Opin Pharmacol 2012; 12:522-6
12. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71
13. David MZ, Glikman D, Crawford SE, et al. What is communityassociated methicillin-resistant Staphylococcus aureus? J Infect Dis 2008; 197:1235-43
14. Chambers HF, DeLeo FR.Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41
15. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-5
16. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55
17. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med 2006; 166:2138-44
18. Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: A retrospective cohort study utilizing the Cubicin® Outcomes Registry and Experience. Clin Ther 2009; 31: 1936-45
19. Fischer A, Yang SJ, Bayer AS, et al. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 2011; 66:1696-711
20. Locke JB, Hilgers M, Shaw KJ. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 2009; 53:5275-8
21. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009; 53:5265-74
22. Livermore DM, Mushtaq S,Warner M,Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009; 63:713-5
23. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11
24. Kanafani ZA, Corey GR. Tedizolid (TR-701): A new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012; 21:515-22
25. Prokocimer P, Bien P, Deanda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against grampositive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:4608-13
26. Louie A, Lui W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55:3453-60
27. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Available at: Http://www.fda.gov/downloads/Drugs/.../Guidances/ ucm071185.pdf. Accessed 19 October 2012
28. European Medicines Agency. Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. Available at: Http://www.ema.europa.eu/docs/enGB/documentlibrary/Scientific guideline/2009/09/WC500003417.pdf. Accessed 17 January 2013
29. Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: Safety summary. Clin Infect Dis 2014; 58:S51-7
30. Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. Pharmacokinetics of tedizolid following oral administration: Single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2013; doi:10.1002/phar.1337
31. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 57:3060-6
32. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial. JAMA 2013; 309:559-69
33. Fang E, De Anda C, Das A, Prokocimer P. Efficacy and safety results from the ESTABLISH 2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid. Poster presented at: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 27-30April 2013; Berlin, Germany
34. Bien P, Prokocimer P, Muñoz KA, Bohn J. The safety of 21-day multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic. Presented at: 19th European Congress of Clinical Microbiology and Infectious Diseases. 16-19 May 2009; Helsinki, Finland. Poster P1089
35. Prokocimer P, Bien P, Muñoz KA, Aster R. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjectsPresented at: 48th Annual ICAAC/IDSA 46th Annual Meeting (ICAAC/IDSA 2008). 25-28 October 2008; Washington, DC. Poster F1-2069a.
36. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, doubleblind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55:583-92
37. Fang E, De Anda C, Das A, Prokocimer P. Safety profile of tedizolid phosphate compared to linezolid in a phase 3 ABSSSI study. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 9-12 September 2012; San Francisco, CA. Poster L1-1664
38. TR-701 FA vs linezolid for the treatment of acute bacterial skin and skin structure infections. Available at: Http://www.clinicaltrials.gov/ct2/ show/NCT01421511. Accessed 22 October 2012
39. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H; on behalf of the CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: Update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 2012; 55:1114-21
40. Trius Therapeutics obtains special protocol assessment with FDA for phase 3 study of torezolid phosphate [press release]. San Diego, CA: Canale Communications, 2010
41. Trius Therapeutics obtains special protocol assessment with FDA for second phase 3 study of torezolid phosphate [press release]. San Diego, CA: Canale Communications, 2011
42. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 2012; 40:51-4
43. Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55:5300-5
44. Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199:804-16
45. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50